HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic

• Unité de recherche: INNOSUISSE
• Numéro de projet: 12667.1;4 PFLS-LS
• Titre du projet anglais: HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic

Description succincte (Allemand)

HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic

Description succincte (Anglais)

HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic

Résumé des résultats (Abstract) (Allemand)

A new and highly innovative treatment will be realized by a novel and patentable orally available small molecule combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic bacterial strains. The consortium integrates medicinal chemistry (Dr. Riedl, ZHAW), biological assays and screening (BioVersys AG) with high-end characterization of binding interactions (Prof. Dr. Gygax, FHNW). HIT compounds identified during two SATW projects will be developed into a clinical candidate utilizing all the experiences in the consortium.

Résumé des résultats (Abstract) (Anglais)

A new and highly innovative treatment will be realized by a novel and patentable orally available small molecule combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic bacterial strains. The consortium integrates medicinal chemistry (Dr. Riedl, ZHAW), biological assays and screening (BioVersys AG) with high-end characterization of binding interactions (Prof. Dr. Gygax, FHNW). HIT compounds identified during two SATW projects will be developed into a clinical candidate utilizing all the experiences in the consortium.